Boehringer Ingelheim Extends the Use of Medidata Rave for Electronic Data Capture in Clinical Trials

Electronic Data Capture
Electronic Data Capture in Clinical Trials

Boehringer Ingelheim and Medidata, a Dassault Systems firm, today announced a five-year extension of their partnership in the broader field of electronic data collection. The new arrangement includes myMedidata, Medidata’s portfolio of cutting-edge patient-facing technologies aimed at boosting patient centricity and diversity in decentralised clinical trials, and also expands the usage of Rave EDC for Boehringer Ingelheim’s clinical trials globally (DCTs).

By supplying Medidata’s scalable patient-centered capabilities, the collaboration strengthens Boehringer Ingelheim’s focus on involving patients in a meaningful way. This includes access to electronic consent, electronic Clinical Outcome Assessment (eCOA), and myMedidata LIVE video investigator/patient interactions through the myMedidata patient portal, a single-destination web-based platform.

“As industry leaders, Boehringer Ingelheim and Medidata have a responsibility to innovate for the benefit of patients”, “Boehringer Ingelheim’s global reach across therapeutic areas is a perfect match for the scalable capabilities of myMedidata and the rest of the Medidata Clinical Cloud platform. Together, we will be able to quickly improve access and diversity of participation in a wide range of clinical programs.”

Anthony Costello, CEO Patient Cloud at Medidata

The industry’s only scalable, end-to-end offering, the Medidata Decentralized Clinical Trials Program, is revolutionising how people give data, how medications are delivered to patients, and how clinical trial data are stored and monitored. The opportunity to increase patient access, inclusion, and participation across geographies as well as to increase patient diversity in clinical trials is provided by these remote technologies, which is of paramount importance.

Technologies from Medidata, such as Rave EDC (electronic data capture), Coder, TSDV (targeted source data verification), and Safety Gateway, have been expanded upon by Boehringer Ingelheim. Additionally, Boehringer Ingelheim is looking into Medidata AI Intelligent Trials to offer cutting-edge analytics to accelerate, succeed, and improve the caliber of clinical trials. Additionally, the company is taking advantage of Medidata Rave Imaging technology through services agreements with the business’ imaging suppliers.

In the era of personalised medicine, Dassault Systemes is well-positioned to lead the digital transformation of the life sciences with its 3DEXPERIENCE platform, which is the first end-to-end scientific and business platform, from research to commercialization. Dassault Systemes owns all of Medidata.

For More Healthcare News Click Here

Next Post

Invitae study shows therapy informed by genetic testing reduces seizures in some patients with epilepsy

Invitae study shows therapy informed by genetic testing reduces seizures in some patients with epilepsy Leading medical genetics business Invitae has released the findings of a study that details the steps clinicians take when patients with epilepsy have a positive diagnostic genetic test result. According to research published in JAMA […]
Invitae study